TMEM59 regulates microglial Aβ phagocytosis in a TREM2‐dependent manner and acts as a potential therapeutic target for Aβ amyloidosis
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Jian Meng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Xiamen Key Laboratory of Brain Center, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, S…. Hauptthemen laut MEDLINE: Microglia, Membrane Glycoproteins, Phagocytosis, Receptors, Immunologic. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Changping Laboratory.
Abstract (Originalsprache)
INTRODUCTION Microglia‐mediated clearance of amyloid beta (Aβ) is crucial for mitigating Alzheimer's disease (AD) progression, yet the molecular regulators of microglial phagocytosis remain incompletely understood. METHODS We assessed AD‐related phenotypes in 5xFAD mice with microglia‐specific deletion of transmembrane protein 59 (TMEM59). Microglial transcriptomic profiling was performed using single‐cell RNA sequencing (scRNA‐seq). A chaperone‐mediated autophagy‐targeting chimera (CMATAC) peptide was developed to degrade TMEM59, and its therapeutic efficacy was evaluated. RESULTS Microglia‐specific TMEM59 ablation attenuated cognitive deficits, Aβ plaque burden, and synapse loss in 5xFAD mice. TMEM59 deficiency reprogrammed disease‐associated microglia toward a highly phagocytic state. Mechanistically, TMEM59 deficiency enhanced microglial Aβ phagocytosis in a triggering receptor expressed on myeloid cells 2 (TREM2)‐dependent manner, as it stabilized TREM2 protein, whereas loss of TREM2 abolished these protective effects. Treatment with the TMEM59‐degrading CMATAC peptide alleviated behavioral deficits and enhanced microglial Aβ phagocytosis in 5xFAD mice. DISCUSSION TMEM59 is a key regulator of microglial phagocytosis in AD and a novel target for amyloidosis intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiamen Key Laboratory of Brain Center, Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, The First Affiliated Hospital of Xiamen University,…
- Center for Geriatric Medicine, International Center for Alzheimer's Research, Prevention and Treatment, Oujiang Laboratory, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, The First Affil…
ORCID-Profile: Yun-Wu Zhang
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Changping Laboratory
Zitieren
APA
Meng, J., Wang, Y., Wang, J., Chen, Y., Zhao, Z., Tang, Z., Cao, J., Zhang, X., Luo, H., Li, H., Wu, Y., Zhao, Y., Song, W., & Zhang, Y. W. (2026). TMEM59 regulates microglial Aβ phagocytosis in a TREM2‐dependent manner and acts as a potential therapeutic target for Aβ amyloidosis. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71873
Vancouver
Meng J, Wang Y, Wang J, Chen Y, Zhao Z, Tang Z, et al. TMEM59 regulates microglial Aβ phagocytosis in a TREM2‐dependent manner and acts as a potential therapeutic target for Aβ amyloidosis. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71873
BibTeX
@article{Meng2026,
author = {Meng, Jian and Wang, Yong and Wang, Jinghui and Chen, Yiqing and Zhao, Zihao and Tang, Ziqian and Cao, Jing and Zhang, Xian and Luo, Hong and Li, Huihui and Wu, Yili and Zhao, Yingjun and Song, Weihong and Zhang, Yun-Wu},
title = {TMEM59 regulates microglial Aβ phagocytosis in a TREM2‐dependent manner and acts as a potential therapeutic target for Aβ amyloidosis},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71873}
}
EUVIMED